NASDAQ · EXEL
Healthcare · Biotechnology
$57.22
Up+$0.93 (+1.63%)
Updated Sep 22, 2026, 10:11 PM
SID Score
7.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
EXEL closed at $57.22 after 20 trading sessions, up 4.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $58.61 | $58.805 | $56.9009 | $57.22 | 2.1M |
| Sep 18, 2026 | $58.285 | $59.15 | $57.895 | $58.36 | 5.24M |
| Sep 17, 2026 | $57.23 | $58.52 | $57.23 | $58.49 | 1.79M |
| Sep 16, 2026 | $57.04 | $57.78 | $56.325 | $56.78 | 1.88M |
| Sep 15, 2026 | $55.93 | $56.97 | $54.945 | $56.90 | 1.98M |
| Sep 14, 2026 | $56.44 | $57.07 | $55.91 | $56.21 | 1.74M |
| Sep 11, 2026 | $56.76 | $57.43 | $54.545 | $56.12 | 2.92M |
| Sep 10, 2026 | $58.33 | $58.33 | $57.23 | $57.43 | 1.79M |
| Sep 9, 2026 | $57.60 | $58.36 | $56.95 | $58.33 | 1.77M |
| Sep 8, 2026 | $58.97 | $59.41 | $57.55 | $57.67 | 2.54M |
| Sep 4, 2026 | $58.502 | $59.255 | $58.455 | $59.01 | 1.58M |
| Sep 3, 2026 | $58.75 | $59.72 | $58.195 | $59.13 | 2.14M |
| Sep 2, 2026 | $57.21 | $59.11 | $56.695 | $58.53 | 2.85M |
| Sep 1, 2026 | $54.75 | $56.97 | $54.75 | $56.89 | 2.41M |
| Aug 31, 2026 | $54.10 | $55.02 | $53.4283 | $54.64 | 2.25M |
| Aug 28, 2026 | $55.14 | $55.25 | $54.12 | $54.45 | 1.49M |
| Aug 27, 2026 | $55.76 | $56.08 | $54.83 | $55.26 | 1.49M |
| Aug 26, 2026 | $56.54 | $56.90 | $56.06 | $56.10 | 1.82M |
| Aug 25, 2026 | $54.95 | $56.74 | $54.95 | $56.72 | 2.02M |
| Aug 24, 2026 | $53.89 | $54.79 | $53.39 | $54.55 | 2.42M |
The latest Smart Investors Daily articles mentioning EXEL.
EXEL research
Company profile and research snapshot.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Market Perform | — |
| Aug 6, 2026 | Truist Securities | Hold | — |
| Aug 6, 2026 | Stifel | Hold | — |
| Jul 23, 2026 | Morgan Stanley | Equal-Weight | — |
| Jul 14, 2026 | Barclays | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 17, 2026
Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer
Yahoo · Sep 17, 2026
Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027. The September 10 notification followed an FDA request for updated safety and efficacy information. The submitted data were classified as a major amendment. The […]
SeekingAlpha · Sep 15, 2026
Exelixis, Inc. (EXEL) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsMichael Morrissey - CEO,...
Yahoo · Sep 15, 2026
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EXEL.
